These are based on a talk given by Michele Bosch at Finnegan
on 8 May 2014. This was a long and
comprehensive talk with many statistics given. The 10 points below reflect my
own observations rather than being an attempt to summarise the talk.
1. The new AIA post
grant trials are:
- Inter Partes
Review (IPR) available on all patents from 16 September 2012 and a Petition
needs to be filed within one year of service of an infringement complaint,
-Post Grant Review (PGR) available from 16 March 2013 on all
‘first-inventor-to-file’ patents and a Petition needs to be filed within 9
months of grant, and
- Transitional Covered Business Method Patent Post-Grant
Review (CBM) available from 16 September 2012 to 2020 on all ‘covered business
method’ patents and a Petitioner must be sued or charged with infringement.
The number of petitions filed as of 2 April 2014 is over
1260 (1100 for IPR, 160 for CBM).
2. There is a strong interest in post-grant trials at the
USPTO because the Patent Trail and Appeal Board (PTAB) is perceived as a ‘friendlier’
forum than the Courts to challenge patents, the costs are lower ($300-400k
versus over $1 million in Court proceedings), there is the possibility of stay
of litigation, it is speedy and has procedural advantages, settlements are possible
at this stage and it may influence the final Court decision. The USPTO construes claims more broadly and there
is no presumption of validity. In
addition the decisions are taken by Administrative Patent Judges who have no problem
in finding patents invalid.
3. The three post-grant trials are different from each other
in many ways. They have different thresholds
before proceedings can be initiated (e.g. IPR has ‘reasonable likelihood of
success’), the proceedings have different grounds on which the patent can be
attacked and they have different estoppel effects. Anonymity is not possible (unlike in reexamination).
4. In the first 18
months of IPR and CBMS some or all claims were cancelled on all patents. However 2 patents have now been upheld with
all claims found to be patentable. Only
15% of petitions are denied. About 10% of instituted proceedings end with settlement. Most trials have been in the areas of
electrical or computer inventions.
5. There are some
similarities to EPO opposition, but there are also real differences. Clearly if the same patent is being attacked
in the two territories, then it is possible to make use of documents from one
proceedings in the other.
6. There are strict page
limits and format requirements for the documents filed during the
proceedings. There are additional strict
criteria for amendment requests, and many amendment requests have failed for procedural
reasons. In fact no amendment requests have been granted to date, apart from
ones where there were only claim deletions.
7. The PTAB is quick
to use redundancy reasons for eliminating grounds and documents, and therefore
thought should be given to explaining why there are distinctions between the
grounds and documents.
8. The PTAB has
stayed ex parte and inter parte re-examination proceedings
when trials are initiated. The Courts
will also tend to stay, but not always.
9. Claim construction
is very important and can often be decisive.
The PTAB is willing to use its own.
10. There is a very
limited discovery process. Additional discovery
beyond the routine is often denied.
You may also be interested in the related articles Top
10 Tips For Success In EPO Appeals on Biotech Cases and Tips
for Opposition Success.
No comments:
Post a Comment